Propel Bio Management LLC Has $12.29 Million Holdings in Phathom Pharmaceuticals, Inc. $PHAT

Posted by Francis Steltz on Jun 7th, 2026

Propel Bio Management LLC boosted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 34.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 740,918 shares of the company’s stock after purchasing an additional 187,991 shares during the period. Phathom Pharmaceuticals makes up approximately 10.5% of Propel Bio Management LLC’s investment portfolio, making the stock its 3rd biggest holding. Propel Bio Management LLC’s holdings in Phathom Pharmaceuticals were worth $12,292,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PHAT. Millennium Management LLC lifted its stake in Phathom Pharmaceuticals by 125.8% in the third quarter. Millennium Management LLC now owns 5,081,451 shares of the company’s stock worth $59,809,000 after purchasing an additional 2,830,954 shares during the last quarter. Moore Capital Management LP bought a new stake in Phathom Pharmaceuticals in the second quarter worth about $5,754,000. Invesco Ltd. lifted its stake in Phathom Pharmaceuticals by 13.4% in the second quarter. Invesco Ltd. now owns 4,140,072 shares of the company’s stock worth $39,703,000 after purchasing an additional 489,260 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Phathom Pharmaceuticals by 15.4% during the third quarter. Vanguard Group Inc. now owns 3,215,572 shares of the company’s stock worth $37,847,000 after acquiring an additional 428,261 shares during the period. Finally, SummitTX Capital L.P. purchased a new position in shares of Phathom Pharmaceuticals during the third quarter worth approximately $4,543,000. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Stock Up 2.7%

NASDAQ:PHAT opened at $10.13 on Friday. Phathom Pharmaceuticals, Inc. has a 52 week low of $4.71 and a 52 week high of $18.31. The firm has a 50 day moving average of $11.60 and a 200 day moving average of $13.04. The stock has a market capitalization of $807.97 million, a price-to-earnings ratio of -4.78 and a beta of 0.50.

Analysts Set New Price Targets

PHAT has been the topic of a number of research reports. Barclays raised shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $16.00 to $18.00 in a research report on Friday, March 27th. Stifel Nicolaus set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Guggenheim raised their target price on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

View Our Latest Research Report on Phathom Pharmaceuticals

About Phathom Pharmaceuticals

(Free Report)

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.